Fact CheckerSign in

NCT07292493Enrolling by invitation

Immune System in Diabetic Kidney Disease

The Role of Complement in Diabetic Kidney Disease

Source: ClinicalTrials.gov · Last updated 23 Feb 2026

Brief summary (registry, in English)

Diabetes is a chronic condition marked by long-term elevated blood glucose levels. There are more types of diabetes; the majority of patients have type 1 or type 2 diabetes. Over long period of time, high blood sugar damages blood vessels and organs. One of the most common complications is diabetic kidney disease, which can slowly lead to kidney failure. People with this condition also have a much higher risk of heart and blood vessel diseases. Newer research shows that the immune system, especially the complement system (a group of proteins that help defend the body), may also play a role in worsening kidney disease in diabetes. High blood sugar can activate these proteins, and they have been found in kidney tissue of patients with diabetic kidney disease. The goal of this study is to find out how much the complement system contributes to kidney damage in diabetes, whether it affects different groups of patients differently, and whether it is linked to blood vessel health or the stage of kidney disease. The study will also assess if improved diabetes control is linked to reduced complement system activity.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
90 (estimated)
First submitted
19 Nov 2025
Start date
1 Dec 2025
Primary completion date
31 Dec 2026
Lead sponsor
University Medical Centre Ljubljana
NCT number
NCT07292493

What you commit to

  • Study type: Observational
  • Planned participants: 90
  • From 1 Dec 2025 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • a body mass index above 30 kg/m²
  • macrovascular complications

Who the study is looking for

  • body mass index below 30 kg/m²
  • unknown macrovascular complications
  • treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at the highest tolerated dose

Age in the registry: 40 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Medical Centre Ljubljana
Coordinator of this site? Confirm its status
LjubljanaSloveniaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.